NCT01428635 2023-09-26
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
Phase 2/3 Completed
Clinical Trials
10 trialsNCT01168921 2023-03-23
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT02071901 2021-12-01
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT01113502 2021-08-05
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT01656252 2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2 Terminated
NCT01893372 2020-02-18
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02010645 2020-01-02
Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed